Blut- und Gewebseosinophilie, Mistellektin-Antikörper und Lebensqualität bei einer Mammakarzinom-Patientin unter intratumoraler und subkutaner Misteltherapie

Abstract

Blood and Tissue Eosinophilia, Mistletoe Lectin Antibodies and Quality of Life in a Breast Cancer Patient Undergoing Intratumoral and Subcutaneous Mistletoe Injection Background: Mistletoe therapy (MT) is a method of complementary medicine whose efficacy is controversially discussed. Until now there is a lack of data of high-dose intratumoral application. Patient and Methods: We are presenting a 3-year follow-up of an 80-year-old woman with metastasized breast cancer (c₂T3/N1/M1) receiving combined intra- and peritumoral and subcutaneous MT with ABNOBAviscum(r)??and concomitant pamitron acid. At time of admission the patient had bone metastases (thoracic vertebra 11 fracture), a lymphangiosis carcinomatosa, bilateral pleural effusions, and a reduced quality of life (QoL). Results: Under MT we induced an eosinophilia and an elevation of eosinophil cationic protein (ECP). Simultaneously, we ascertained a reduction of 50% of Ca 15-3 and a sustained partial tumor remission. After 5 months the mistletoe-lectin-1 antibodies IgG-1 and -3 were maximally increased and we perceived a second Ca 15-3 reduction. After 3 months we observed a benefit in QoL. During the following 5 months the patient gained about 10 kg in weight. In the second year slow tumor progress was observed. After 19 months the patient had pneumonia which caused an MT pause. Subsequently, a combined intratumoral mistletoe and letrozol therapy brought a partial remission. The patient lived without chemoand radiation therapy more than 3 years with good QoL and died after 41 months, after a sepsis and a following stroke without signs of tumor progress. Conclusion: In metastasized breast cancer a palliative high-dose local MT can make a contribution to a tumor reduction and a benefit in QoL.

The Internal Coherence of Breast Cancer Patients Is Associated with the Decision‐Making for Chemotherapy and Viscum album L. Treatment

“…VA-applications are usually well tolerated and had only few and mild side-effects [ 23 – 25 ]. Various reports support clinical findings that VA-therapy can improve and stabilize HRQL in cancer patients, especially in breast cancer during CTX [ 26 – 29 ]. In this noninterventional, observational study, the ICS was used to evaluate the effects of add-on VA-therapy on the internal coherence in breast cancer patients with the advice for CTX.…”

Preclinical and Clinical Effects of Mistletoe against Breast Cancer

“…The authors found sufficient evidence to recommend the use of Iscador for treatment of cancer in breast cancer patients with or without axillary metastases. In 2002, Kröz et al [ 92 ] reported some benefits of mistletoe therapy in survival and tumor reduction in women with metastasized breast cancer. They applied combined intra-, peritumoral, and subcutaneous abnoba-Viscum(r) with concomitant pamitron acid to breast cancer patients.…”